董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 费凯宁 | 女 | Director | 63 | 5.42万美元 | 未持股 | 2021-04-30 |
| Todd Shegog | 男 | Director | 56 | 未披露 | 未持股 | 2021-04-30 |
| Andrew Robbins | 男 | Chief Executive Officer, President and Director | 45 | 1785.97万美元 | 未持股 | 2021-04-30 |
| Chris Cain | 男 | Director | 37 | 7.47万美元 | 未持股 | 2021-04-30 |
| Peter Harwin | 男 | Chairman and Director | 35 | 9.29万美元 | 未持股 | 2021-04-30 |
| Matthew E. Ros | 男 | Director | 54 | 5.32万美元 | 未持股 | 2021-04-30 |
| Arlene M. Morris | 女 | Director | 69 | 6.07万美元 | 未持股 | 2021-04-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew Robbins | 男 | Chief Executive Officer, President and Director | 45 | 1785.97万美元 | 未持股 | 2021-04-30 |
| John Green | 男 | Chief Financial Officer | 40 | 213.92万美元 | 未持股 | 2021-04-30 |
| Jessica Sachs | 女 | Chief Medical Officer | 46 | 118.95万美元 | 未持股 | 2021-04-30 |
董事简历
中英对照 | 中文 | 英文- 费凯宁
-
费凯宁，自2017年2月起担任和黄医药（中国）有限公司独立非执行董事。她亦为技术委员会主席及审核委员会成员。她于制药行业拥有逾26年经验。她为Tokai Pharmaceuticals, Inc.（一家致力于开发及商业化用于前列腺癌及其他激素引发疾病的创新疗法的生物制药公司）的前首席医务官及研发主管。Ferrante博士先前于Millennium Pharmaceuticals, Inc.及其母公司武田制药有限公司担任多个高级职位，包括首席医务官及最近期担任肿瘤治疗领域及美国剑桥场址的负责人。她亦于辉瑞公司担任越来越重要的职务，最后职位为肿瘤开发部副总裁。Ferrante博士现任MacroGenics,Inc.（于纳斯达克上市，股份代号：MGNX）及Cogent Biosciences, Inc.（前称Unum Therapeutics Inc.，于纳斯达克上市，股份代号：COGT）的董事会成员。Ferrante博士过往曾任Baxalta Incorporated董事（直至该公司于2016年被Shire plc收购）及Progenics Pharmaceuticals, Inc.（曾于纳斯达克上市，股份代号：PGNX）董事（直至该公司于2020年被Lantheus Holdings, Inc.收购）。她在肿瘤学领域发表多篇论文，积极参与学术及专业协会及研讨会并持有多项专利。Ferrante博士于1980年5月在普洛威顿斯学院取得化学及生物学理学学士学位及于1988年5月在乔治城大学取得医学博士学位。
Karen Ferrante,has been an independent non-executive director of Hutchmed (China) Limited since 2017. She is also chairman of Hutchmed (China) Limited technical committee and a member of Hutchmed (China) Limited audit committee. She has more than 26 years of experience in the pharmaceutical industry. She was the former chief medical officer and head of research and development of Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. Dr. Ferrante previously held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including chief medical officer and most recently as oncology therapeutic area and Cambridge USA site head. She had also held positions of increasing responsibility at Pfizer Inc. ("Pfizer"), with the last position as vice president, oncology development. Dr. Ferrante is currently a member of the board of directors of MacroGenics, Inc., and Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.). Dr. Ferrante was previously a director of Baxalta Incorporated until it was acquired by Shire plc in 2016 and a director of Progenics Pharmaceuticals, Inc., until it was acquired by Lantheus Holdings, Inc. in 2020. She was previously a member of the scientific advisory board of Trillium Therapeutics Inc. until it was acquired by Pfizer in November 2021. She was also a past member of the Scientific Advisory Board of Kazia Therapeutics Limited. Dr. Ferrante is an author of a number of papers in the field of oncology, an active participant in academic and professional associations and symposia and holder of several patents. Dr. Ferrante received a bachelor of science degree in chemistry and biology from Providence College and a doctor of medicine from Georgetown University. - 费凯宁，自2017年2月起担任和黄医药（中国）有限公司独立非执行董事。她亦为技术委员会主席及审核委员会成员。她于制药行业拥有逾26年经验。她为Tokai Pharmaceuticals, Inc.（一家致力于开发及商业化用于前列腺癌及其他激素引发疾病的创新疗法的生物制药公司）的前首席医务官及研发主管。Ferrante博士先前于Millennium Pharmaceuticals, Inc.及其母公司武田制药有限公司担任多个高级职位，包括首席医务官及最近期担任肿瘤治疗领域及美国剑桥场址的负责人。她亦于辉瑞公司担任越来越重要的职务，最后职位为肿瘤开发部副总裁。Ferrante博士现任MacroGenics,Inc.（于纳斯达克上市，股份代号：MGNX）及Cogent Biosciences, Inc.（前称Unum Therapeutics Inc.，于纳斯达克上市，股份代号：COGT）的董事会成员。Ferrante博士过往曾任Baxalta Incorporated董事（直至该公司于2016年被Shire plc收购）及Progenics Pharmaceuticals, Inc.（曾于纳斯达克上市，股份代号：PGNX）董事（直至该公司于2020年被Lantheus Holdings, Inc.收购）。她在肿瘤学领域发表多篇论文，积极参与学术及专业协会及研讨会并持有多项专利。Ferrante博士于1980年5月在普洛威顿斯学院取得化学及生物学理学学士学位及于1988年5月在乔治城大学取得医学博士学位。
- Karen Ferrante,has been an independent non-executive director of Hutchmed (China) Limited since 2017. She is also chairman of Hutchmed (China) Limited technical committee and a member of Hutchmed (China) Limited audit committee. She has more than 26 years of experience in the pharmaceutical industry. She was the former chief medical officer and head of research and development of Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. Dr. Ferrante previously held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including chief medical officer and most recently as oncology therapeutic area and Cambridge USA site head. She had also held positions of increasing responsibility at Pfizer Inc. ("Pfizer"), with the last position as vice president, oncology development. Dr. Ferrante is currently a member of the board of directors of MacroGenics, Inc., and Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.). Dr. Ferrante was previously a director of Baxalta Incorporated until it was acquired by Shire plc in 2016 and a director of Progenics Pharmaceuticals, Inc., until it was acquired by Lantheus Holdings, Inc. in 2020. She was previously a member of the scientific advisory board of Trillium Therapeutics Inc. until it was acquired by Pfizer in November 2021. She was also a past member of the Scientific Advisory Board of Kazia Therapeutics Limited. Dr. Ferrante is an author of a number of papers in the field of oncology, an active participant in academic and professional associations and symposia and holder of several patents. Dr. Ferrante received a bachelor of science degree in chemistry and biology from Providence College and a doctor of medicine from Georgetown University.
- Todd Shegog
-
Todd Shegog自2019年9月起担任我们的高级副总裁兼首席财务官。在加入公司之前，Shegog先生于2016年9月至2019年9月担任上市公司Synlogic，Inc.的首席财务官。2014年4月至2016年8月，他担任Forum Pharmaceuticals，Inc.的高级副总裁和首席财务官。任职Forum公司之前，他曾担任Millennium Pharmaceuticals公司（武田肿瘤公司）的高级副总裁，财务和首席财务官（从2008年到2014年3月）。Shegog先生拥有拉斐特学院（Lafayette College）的电气工程学士学位和卡内基梅隆大学（Carnegie Mellon University）泰珀商学院（Tepper School of Business）的金融工商管理硕士学位。
Todd Shegog has served as a member of our Board since February 2021. Mr. Shegog has more than 25 years of financial, operations, corporate strategy and compliance expertise in the biotechnology and pharmaceutical industries. He has served as Senior Vice President and Chief Financial Officer of Forma Therapeutics Nasdaq: FMTX, a clinical-stage biopharmaceutical company, since September 2019. Prior to Forma Therapeutics, Mr. Shegog served as Chief Financial Officer of Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biopharmaceutical company, where he directed the company's financial strategy and management as well as facilities and information systems from September 2016 to September 2019. From April 2014 to August 2016 Mr. Shegog served as Senior Vice President and Chief Financial Officer at Forum Pharmaceuticals, Inc., an early-stage biopharmaceutical company, where he was responsible for finance, operations and information systems during their pursuit of innovative therapies for schizophrenia and Alzheimer's disease. He also served as the Chief Financial Officer of Millennium Pharmaceuticals, Inc., now Takeda Oncology, where he was responsible for management of the company's financial resources, corporate planning, financial reporting and compliance from 1998 to 2014. Mr. Shegog earned a B.S. in electrical engineering from Lafayette College and an M.B.A. from the Tepper School of Management at Carnegie Mellon University. - Todd Shegog自2019年9月起担任我们的高级副总裁兼首席财务官。在加入公司之前，Shegog先生于2016年9月至2019年9月担任上市公司Synlogic，Inc.的首席财务官。2014年4月至2016年8月，他担任Forum Pharmaceuticals，Inc.的高级副总裁和首席财务官。任职Forum公司之前，他曾担任Millennium Pharmaceuticals公司（武田肿瘤公司）的高级副总裁，财务和首席财务官（从2008年到2014年3月）。Shegog先生拥有拉斐特学院（Lafayette College）的电气工程学士学位和卡内基梅隆大学（Carnegie Mellon University）泰珀商学院（Tepper School of Business）的金融工商管理硕士学位。
- Todd Shegog has served as a member of our Board since February 2021. Mr. Shegog has more than 25 years of financial, operations, corporate strategy and compliance expertise in the biotechnology and pharmaceutical industries. He has served as Senior Vice President and Chief Financial Officer of Forma Therapeutics Nasdaq: FMTX, a clinical-stage biopharmaceutical company, since September 2019. Prior to Forma Therapeutics, Mr. Shegog served as Chief Financial Officer of Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biopharmaceutical company, where he directed the company's financial strategy and management as well as facilities and information systems from September 2016 to September 2019. From April 2014 to August 2016 Mr. Shegog served as Senior Vice President and Chief Financial Officer at Forum Pharmaceuticals, Inc., an early-stage biopharmaceutical company, where he was responsible for finance, operations and information systems during their pursuit of innovative therapies for schizophrenia and Alzheimer's disease. He also served as the Chief Financial Officer of Millennium Pharmaceuticals, Inc., now Takeda Oncology, where he was responsible for management of the company's financial resources, corporate planning, financial reporting and compliance from 1998 to 2014. Mr. Shegog earned a B.S. in electrical engineering from Lafayette College and an M.B.A. from the Tepper School of Management at Carnegie Mellon University.
- Andrew Robbins
-
Andrew Robbins自2020年3月起担任董事会成员。Robbins先生于2015年3月起担任制药公司Array BiopharmaInc.的首席运营官，直至2019年7月被制药公司辉瑞公司收购，并于2012年7月至2015年3月担任其高级副总裁，商业运营。从2007年1月至2012年7月，Robbins先生在好比拉医疗保健公司公司（一家制药和医疗设备公司）担任管理职位，包括美国备用站点业务部总经理兼Vice President和企业发展Vice President。任职Hospira公司之前，Robbins先生曾担任Pfizer’；s肿瘤科的商业和领导职务。Robbins先生拥有斯沃斯莫尔学院（Swarthmore College）的学士学位和西北大学凯洛格管理学院（Kellogg School of Management）的工商管理硕士学位。
Andrew Robbins has served as our Chief Executive Officer, President, principal executive officer and a member of our Board since October 2020. Prior to joining Cogent, Mr. Robbins served as Chief Operating Officer at Array BioPharma Inc., a pharmaceutical company, from March 2015 through its acquisition by Pfizer Inc., a pharmaceutical company, in July 2019 after serving as its Senior Vice President, Commercial Operations from July 2012 to March 2015. From January 2007 to July 2012 Mr. Robbins held management positions at Hospira, Inc., a pharmaceutical and medical device company, including General Manager and Vice President of the U.S. Alternate Site business unit and Vice President of Corporate Development. Prior to Hospira, Mr. Robbins held commercial and leadership positions within Pfizer's oncology unit. Additionally, Mr. Robbins currently serves on the board of directors for Harpoon Therapeutics Nasdaq: HARP and Turmeric Acquisition Corporation (Nasdaq: TMPMU). Mr. Robbins holds an M.B.A. from the Kellogg School of Management, Northwestern University and a bachelor's degree from Swarthmore College. - Andrew Robbins自2020年3月起担任董事会成员。Robbins先生于2015年3月起担任制药公司Array BiopharmaInc.的首席运营官，直至2019年7月被制药公司辉瑞公司收购，并于2012年7月至2015年3月担任其高级副总裁，商业运营。从2007年1月至2012年7月，Robbins先生在好比拉医疗保健公司公司（一家制药和医疗设备公司）担任管理职位，包括美国备用站点业务部总经理兼Vice President和企业发展Vice President。任职Hospira公司之前，Robbins先生曾担任Pfizer’；s肿瘤科的商业和领导职务。Robbins先生拥有斯沃斯莫尔学院（Swarthmore College）的学士学位和西北大学凯洛格管理学院（Kellogg School of Management）的工商管理硕士学位。
- Andrew Robbins has served as our Chief Executive Officer, President, principal executive officer and a member of our Board since October 2020. Prior to joining Cogent, Mr. Robbins served as Chief Operating Officer at Array BioPharma Inc., a pharmaceutical company, from March 2015 through its acquisition by Pfizer Inc., a pharmaceutical company, in July 2019 after serving as its Senior Vice President, Commercial Operations from July 2012 to March 2015. From January 2007 to July 2012 Mr. Robbins held management positions at Hospira, Inc., a pharmaceutical and medical device company, including General Manager and Vice President of the U.S. Alternate Site business unit and Vice President of Corporate Development. Prior to Hospira, Mr. Robbins held commercial and leadership positions within Pfizer's oncology unit. Additionally, Mr. Robbins currently serves on the board of directors for Harpoon Therapeutics Nasdaq: HARP and Turmeric Acquisition Corporation (Nasdaq: TMPMU). Mr. Robbins holds an M.B.A. from the Kellogg School of Management, Northwestern University and a bachelor's degree from Swarthmore College.
- Chris Cain
-
Chris Cain自2020年7月起担任我们的董事会成员，是医疗保健投资基金Fairmount Funds Management LLC“Fairmount Funds”的指定人。Cain博士自2020年4月以来一直担任Fairmount Funds的研究总监。从2019年2月至2020年2月，Cain博士担任专注于生物治疗的风险投资基金Samsara Biocapital的副总裁。在担任该职位之前，该隐博士于2016年7月至2019年1月在专注于生命科学的风险投资基金Apple Tree Partners任职，最近担任高级合伙人。Cain博士于2014年11月至2016年5月担任投资管理公司RA Capital Management的合伙人。在此之前，Cain博士于2010年6月至2014年10月在BioCentury Publications任职，最近担任副主编。他在加州大学圣巴巴拉分校获得文学士学位，在加州大学旧金山分校获得生物化学和分子生物学博士学位。
Chris Cain has served as a member of our Board since July 2020 and is a designee of Fairmount Funds Management LLC "Fairmount Funds", a healthcare investment fund. Dr. Cain has served as Director of Research at Fairmount Funds since April 2020. From February 2019 to February 2020 Dr. Cain served as Vice President at Samsara BioCapital, a biotherapeutics-focused venture capital fund. Prior to that role, Dr. Cain served at Apple Tree Partners, a life sciences-focused venture capital fund, from July 2016 to January 2019 most recently as Senior Associate. Dr. Cain served as an Associate at RA Capital Management, an investment management company, from November 2014 to May 2016. Before this, Dr. Cain served at BioCentury Publications from June 2010 to October 2014 most recently as Associate Editor. He received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco. - Chris Cain自2020年7月起担任我们的董事会成员，是医疗保健投资基金Fairmount Funds Management LLC“Fairmount Funds”的指定人。Cain博士自2020年4月以来一直担任Fairmount Funds的研究总监。从2019年2月至2020年2月，Cain博士担任专注于生物治疗的风险投资基金Samsara Biocapital的副总裁。在担任该职位之前，该隐博士于2016年7月至2019年1月在专注于生命科学的风险投资基金Apple Tree Partners任职，最近担任高级合伙人。Cain博士于2014年11月至2016年5月担任投资管理公司RA Capital Management的合伙人。在此之前，Cain博士于2010年6月至2014年10月在BioCentury Publications任职，最近担任副主编。他在加州大学圣巴巴拉分校获得文学士学位，在加州大学旧金山分校获得生物化学和分子生物学博士学位。
- Chris Cain has served as a member of our Board since July 2020 and is a designee of Fairmount Funds Management LLC "Fairmount Funds", a healthcare investment fund. Dr. Cain has served as Director of Research at Fairmount Funds since April 2020. From February 2019 to February 2020 Dr. Cain served as Vice President at Samsara BioCapital, a biotherapeutics-focused venture capital fund. Prior to that role, Dr. Cain served at Apple Tree Partners, a life sciences-focused venture capital fund, from July 2016 to January 2019 most recently as Senior Associate. Dr. Cain served as an Associate at RA Capital Management, an investment management company, from November 2014 to May 2016. Before this, Dr. Cain served at BioCentury Publications from June 2010 to October 2014 most recently as Associate Editor. He received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco.
- Peter Harwin
-
Peter Harwin自2020年7月以来一直担任我们的董事会成员，是Fairmount Funds的指定人。他目前是Fairmount Funds（他于2016年4月联合创立的医疗保健投资基金）的管理成员。在加入Fairmount Funds之前，Harwin先生曾担任Boxer Capital，LLC（Tavistock Group的一部分，位于圣地亚哥）的投资团队成员，最近担任该团队的高级成员。除了在Fairmount Funds的职责外，Harwin先生还担任Dianthus Therapeutics，Inc.的战略顾问。Harwin先生还担任Viridian Therapeutics，Inc.的董事会成员。纳斯达克:VRDN。Harwin先生在埃默里大学获得了学士学位。
Peter Harwin has served as a member of our Board since October 2020. Mr. Harwin is currently a managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Harwin served as a member of the investment team at Boxer Capital, LLC, a private biotechnology investment fund as part of the Tavistock Group, based in San Diego, most recently serving as a senior member of the team. In addition to his responsibilities at Fairmount, Mr. Harwin serves as a strategic advisor to biotechnology companies Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. Mr. Harwin currently serves as Chairman of the Board for Cogent Biosciences, Inc., a publicly-traded biopharmaceutical company. He received his Bachelor of Business Administration degree from Emory University. - Peter Harwin自2020年7月以来一直担任我们的董事会成员，是Fairmount Funds的指定人。他目前是Fairmount Funds（他于2016年4月联合创立的医疗保健投资基金）的管理成员。在加入Fairmount Funds之前，Harwin先生曾担任Boxer Capital，LLC（Tavistock Group的一部分，位于圣地亚哥）的投资团队成员，最近担任该团队的高级成员。除了在Fairmount Funds的职责外，Harwin先生还担任Dianthus Therapeutics，Inc.的战略顾问。Harwin先生还担任Viridian Therapeutics，Inc.的董事会成员。纳斯达克:VRDN。Harwin先生在埃默里大学获得了学士学位。
- Peter Harwin has served as a member of our Board since October 2020. Mr. Harwin is currently a managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Harwin served as a member of the investment team at Boxer Capital, LLC, a private biotechnology investment fund as part of the Tavistock Group, based in San Diego, most recently serving as a senior member of the team. In addition to his responsibilities at Fairmount, Mr. Harwin serves as a strategic advisor to biotechnology companies Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. Mr. Harwin currently serves as Chairman of the Board for Cogent Biosciences, Inc., a publicly-traded biopharmaceutical company. He received his Bachelor of Business Administration degree from Emory University.
- Matthew E. Ros
-
Matthew E. Ros自2009年1月以来担任我们商业运营的高级副总裁。他之前从2007年11月到2008年12月担任商业运营的副总裁和肿瘤学营销的副总裁。他从1990年到2007年在BMS担任一系列高级销售，营销和运营管理职位，最近担任高级主管和美国商业领导，负责肿瘤产品的启动和商业化。他之前担任的职位包括肿瘤系列规划和发展的主管；肿瘤全球营销的主管；销售培训和推广的主管。他获得纽约州立大学（the State University of New York）的学士学位。
Matthew E. Ros has served as a member of our Board since July 2019. Mr. Ros has served as Chief Strategy and Business Officer of Epizyme, a late-stage biopharmaceutical company, since September 2018. He served as Chief Operating Officer of Epizyme from May 2016 to September 2018. Prior to joining Epizyme, from September 2010 to May 2016 Mr. Ros served in increasing levels of responsibility at Sanofi, a multinational pharmaceutical company, most recently as Chief Operating Officer/Global Head of the Oncology business unit from December 2014 to May 2016. Prior to that role, Mr. Ros served in the rare disease business of Genzyme, a Sanofi company, where he served as Vice President and Franchise Head of its Pompe disease unit from September 2012 to December 2014 and also served as the Associate Vice President and Iniparib Global Brand Leader in Sanofi's Oncology business unit from September 2010 to September 2012. From October 2007 to June 2010 Mr. Ros served at ARIAD Pharmaceuticals, Inc., a global oncology company, most recently as Senior Vice President, Commercial Operations. He started his pharmaceutical career in Bristol-Myers Squibb's Oncology Division, serving in roles with increasing responsibility from 1990 to 2007. He received a B.S. from the State University of New York, College at Plattsburgh and completed the Executive Education Program in Finance and Accounting for the Non-Financial Manager at Wharton School of the University of Pennsylvania. - Matthew E. Ros自2009年1月以来担任我们商业运营的高级副总裁。他之前从2007年11月到2008年12月担任商业运营的副总裁和肿瘤学营销的副总裁。他从1990年到2007年在BMS担任一系列高级销售，营销和运营管理职位，最近担任高级主管和美国商业领导，负责肿瘤产品的启动和商业化。他之前担任的职位包括肿瘤系列规划和发展的主管；肿瘤全球营销的主管；销售培训和推广的主管。他获得纽约州立大学（the State University of New York）的学士学位。
- Matthew E. Ros has served as a member of our Board since July 2019. Mr. Ros has served as Chief Strategy and Business Officer of Epizyme, a late-stage biopharmaceutical company, since September 2018. He served as Chief Operating Officer of Epizyme from May 2016 to September 2018. Prior to joining Epizyme, from September 2010 to May 2016 Mr. Ros served in increasing levels of responsibility at Sanofi, a multinational pharmaceutical company, most recently as Chief Operating Officer/Global Head of the Oncology business unit from December 2014 to May 2016. Prior to that role, Mr. Ros served in the rare disease business of Genzyme, a Sanofi company, where he served as Vice President and Franchise Head of its Pompe disease unit from September 2012 to December 2014 and also served as the Associate Vice President and Iniparib Global Brand Leader in Sanofi's Oncology business unit from September 2010 to September 2012. From October 2007 to June 2010 Mr. Ros served at ARIAD Pharmaceuticals, Inc., a global oncology company, most recently as Senior Vice President, Commercial Operations. He started his pharmaceutical career in Bristol-Myers Squibb's Oncology Division, serving in roles with increasing responsibility from 1990 to 2007. He received a B.S. from the State University of New York, College at Plattsburgh and completed the Executive Education Program in Finance and Accounting for the Non-Financial Manager at Wharton School of the University of Pennsylvania.
- Arlene M. Morris
-
Arlene M. Morris，她一直担任Palatin的董事（2015年6月以来）。自2015年5月起，她担任Willow Advisors, LLC（生物技术公司的业务发展、商业发展和企业战略咨询公司）的首席执行官。2012年4月至2015年5月，她担任Syndax Pharmaceuticals, Inc.（一家私营生物制药公司，专注于治疗耐药癌症的表观遗传疗法的开发和商业化）的总裁兼首席执行官，并于2011年5月至2015年5月担任董事会成员。2003年至2011年1月，她担任Affymax, Inc.（上市的生物技术公司）的总裁、首席执行官和董事会成员。她还曾在Clearview Projects, Inc.（企业咨询公司）、Coulter Pharmaceutical, Inc.（公开上市的制药公司）、Scios Inc.（公开上市的生物制药公司）和Johnson & Johnson（公开上市的医疗保健公司）担任各种管理和执行职位。她目前是Viridian Therapeutics, Inc.（公开交易的治疗抗体公司）和Cogent Biosciences, Inc.（公开交易的肿瘤生物制药公司）的董事会成员，并曾担任Viveve Medical, Inc.（公开交易的女性医疗保健医疗设备公司）的董事，直到2023年2月，Neovacs SA（公开交易的法国公司），Biodel Inc.（公开交易的专业制药公司）。从2015年到2016年与Albireo Limited和Dimension Therapeutics, Inc.（上市的基因治疗公司）合并，直到2017年被Ultragenyx Pharmaceutical Inc.收购。她持有Carlow College的生物和化学学士学位。
Arlene M. Morris,has been a director of Palatin since June 2015. Since May 2015 she has served as the chief executive officer of Willow Advisors, LLC, a consultancy to biotech companies on business development, commercial development and corporate strategy. From April 2012 until May 2015, she was President and Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers, and was a member of the board of directors from May 2011 until May 2015. From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors Viridian Therapeutics, Inc. (NASDAQ: VRDN), a publicly traded therapeutic antibody company, and Cogent Biosciences, Inc. (NASDAQ: COGT), a publicly traded oncology biopharmaceutical company, is a director (since February 2022) and currently chair of TC Biopharm (Holdings) PLC (Nasdaq: TCBP), a United Kingdom biopharmaceutical company, and was previously a director of Viveve Medical, Inc., a publicly traded female healthcare medical device company, until February 2023, Neovacs SA, a publicly traded French company, Biodel Inc., a publicly traded specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016, and Dimension Therapeutics, Inc., a publicly traded gene therapy company, until its acquisition by Ultragenyx Pharmaceutical Inc. in 2017. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College. - Arlene M. Morris，她一直担任Palatin的董事（2015年6月以来）。自2015年5月起，她担任Willow Advisors, LLC（生物技术公司的业务发展、商业发展和企业战略咨询公司）的首席执行官。2012年4月至2015年5月，她担任Syndax Pharmaceuticals, Inc.（一家私营生物制药公司，专注于治疗耐药癌症的表观遗传疗法的开发和商业化）的总裁兼首席执行官，并于2011年5月至2015年5月担任董事会成员。2003年至2011年1月，她担任Affymax, Inc.（上市的生物技术公司）的总裁、首席执行官和董事会成员。她还曾在Clearview Projects, Inc.（企业咨询公司）、Coulter Pharmaceutical, Inc.（公开上市的制药公司）、Scios Inc.（公开上市的生物制药公司）和Johnson & Johnson（公开上市的医疗保健公司）担任各种管理和执行职位。她目前是Viridian Therapeutics, Inc.（公开交易的治疗抗体公司）和Cogent Biosciences, Inc.（公开交易的肿瘤生物制药公司）的董事会成员，并曾担任Viveve Medical, Inc.（公开交易的女性医疗保健医疗设备公司）的董事，直到2023年2月，Neovacs SA（公开交易的法国公司），Biodel Inc.（公开交易的专业制药公司）。从2015年到2016年与Albireo Limited和Dimension Therapeutics, Inc.（上市的基因治疗公司）合并，直到2017年被Ultragenyx Pharmaceutical Inc.收购。她持有Carlow College的生物和化学学士学位。
- Arlene M. Morris,has been a director of Palatin since June 2015. Since May 2015 she has served as the chief executive officer of Willow Advisors, LLC, a consultancy to biotech companies on business development, commercial development and corporate strategy. From April 2012 until May 2015, she was President and Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers, and was a member of the board of directors from May 2011 until May 2015. From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors Viridian Therapeutics, Inc. (NASDAQ: VRDN), a publicly traded therapeutic antibody company, and Cogent Biosciences, Inc. (NASDAQ: COGT), a publicly traded oncology biopharmaceutical company, is a director (since February 2022) and currently chair of TC Biopharm (Holdings) PLC (Nasdaq: TCBP), a United Kingdom biopharmaceutical company, and was previously a director of Viveve Medical, Inc., a publicly traded female healthcare medical device company, until February 2023, Neovacs SA, a publicly traded French company, Biodel Inc., a publicly traded specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016, and Dimension Therapeutics, Inc., a publicly traded gene therapy company, until its acquisition by Ultragenyx Pharmaceutical Inc. in 2017. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College.
高管简历
中英对照 | 中文 | 英文- Andrew Robbins
Andrew Robbins自2020年3月起担任董事会成员。Robbins先生于2015年3月起担任制药公司Array BiopharmaInc.的首席运营官，直至2019年7月被制药公司辉瑞公司收购，并于2012年7月至2015年3月担任其高级副总裁，商业运营。从2007年1月至2012年7月，Robbins先生在好比拉医疗保健公司公司（一家制药和医疗设备公司）担任管理职位，包括美国备用站点业务部总经理兼Vice President和企业发展Vice President。任职Hospira公司之前，Robbins先生曾担任Pfizer’；s肿瘤科的商业和领导职务。Robbins先生拥有斯沃斯莫尔学院（Swarthmore College）的学士学位和西北大学凯洛格管理学院（Kellogg School of Management）的工商管理硕士学位。
Andrew Robbins has served as our Chief Executive Officer, President, principal executive officer and a member of our Board since October 2020. Prior to joining Cogent, Mr. Robbins served as Chief Operating Officer at Array BioPharma Inc., a pharmaceutical company, from March 2015 through its acquisition by Pfizer Inc., a pharmaceutical company, in July 2019 after serving as its Senior Vice President, Commercial Operations from July 2012 to March 2015. From January 2007 to July 2012 Mr. Robbins held management positions at Hospira, Inc., a pharmaceutical and medical device company, including General Manager and Vice President of the U.S. Alternate Site business unit and Vice President of Corporate Development. Prior to Hospira, Mr. Robbins held commercial and leadership positions within Pfizer's oncology unit. Additionally, Mr. Robbins currently serves on the board of directors for Harpoon Therapeutics Nasdaq: HARP and Turmeric Acquisition Corporation (Nasdaq: TMPMU). Mr. Robbins holds an M.B.A. from the Kellogg School of Management, Northwestern University and a bachelor's degree from Swarthmore College.- Andrew Robbins自2020年3月起担任董事会成员。Robbins先生于2015年3月起担任制药公司Array BiopharmaInc.的首席运营官，直至2019年7月被制药公司辉瑞公司收购，并于2012年7月至2015年3月担任其高级副总裁，商业运营。从2007年1月至2012年7月，Robbins先生在好比拉医疗保健公司公司（一家制药和医疗设备公司）担任管理职位，包括美国备用站点业务部总经理兼Vice President和企业发展Vice President。任职Hospira公司之前，Robbins先生曾担任Pfizer’；s肿瘤科的商业和领导职务。Robbins先生拥有斯沃斯莫尔学院（Swarthmore College）的学士学位和西北大学凯洛格管理学院（Kellogg School of Management）的工商管理硕士学位。
- Andrew Robbins has served as our Chief Executive Officer, President, principal executive officer and a member of our Board since October 2020. Prior to joining Cogent, Mr. Robbins served as Chief Operating Officer at Array BioPharma Inc., a pharmaceutical company, from March 2015 through its acquisition by Pfizer Inc., a pharmaceutical company, in July 2019 after serving as its Senior Vice President, Commercial Operations from July 2012 to March 2015. From January 2007 to July 2012 Mr. Robbins held management positions at Hospira, Inc., a pharmaceutical and medical device company, including General Manager and Vice President of the U.S. Alternate Site business unit and Vice President of Corporate Development. Prior to Hospira, Mr. Robbins held commercial and leadership positions within Pfizer's oncology unit. Additionally, Mr. Robbins currently serves on the board of directors for Harpoon Therapeutics Nasdaq: HARP and Turmeric Acquisition Corporation (Nasdaq: TMPMU). Mr. Robbins holds an M.B.A. from the Kellogg School of Management, Northwestern University and a bachelor's degree from Swarthmore College.
- John Green
John Green自2020年7月起担任我们的首席财务官，首席会计官兼首席财务官。在晋升之前，格林先生于2018年4月至2020年6月担任我们的财务副总裁兼财务总监。Green先生为他的职位带来了近20年的战略财务和会计经验，其中近一半在公共和私人公司的生物技术行业。在加入Cogent之前，Green先生担任Merrimack Pharmaceuticals, Inc.的首席会计官。纳斯达克:Mack，一家生物制药公司，从2017年3月至2018年6月。从2015年11月至2017年3月，他担任医疗技术公司Fractyl Laboratories，Inc.的财务总监。2014年6月至2015年11月，Green先生担任生物制药公司Dicerna Pharmaceuticals, Inc.的会计总监。从2013年11月到2014年6月，Green先生担任Corporate Finance Group，Inc.的高级经理，这是一家金融咨询公司。从2008年到2013年9月，Green先生担任普华永道会计师事务所（PricewaterhouseCoopers LLP，一家会计师事务所）的保证经理。Green先生是一名注册专业会计师，拥有阿卡迪亚大学化学和生物学学士学位。
John Green has served as our Chief Financial Officer, principal accounting officer and principal financial officer since July 2020. Prior to his promotion, Mr. Green was our Vice President of Finance and Controller from April 2018 to June 2020.Prior to joining Cogent, Mr. Green served as Principal Accounting Officer at Merrimack Pharmaceuticals, Inc. Nasdaq: MACK, a biopharmaceutical company, from March 2017 to June 2018. From November 2015 to March 2017 he served as the Controller at Fractyl Laboratories, Inc., a medical technology company. From June 2014 to November 2015 Mr. Green served as Director of Accounting at Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a biopharmaceutical company. From November 2013 to June 2014 Mr. Green served as a Senior Manager at Corporate Finance Group, Inc., a financial consulting firm. From 2008 to September 2013 Mr. Green served as an Assurance Manager at PricewaterhouseCoopers LLP, an accounting firm. Mr. Green is a Chartered Professional Accountant and holds a B.S. in Chemistry and Biology from Acadia University.- John Green自2020年7月起担任我们的首席财务官，首席会计官兼首席财务官。在晋升之前，格林先生于2018年4月至2020年6月担任我们的财务副总裁兼财务总监。Green先生为他的职位带来了近20年的战略财务和会计经验，其中近一半在公共和私人公司的生物技术行业。在加入Cogent之前，Green先生担任Merrimack Pharmaceuticals, Inc.的首席会计官。纳斯达克:Mack，一家生物制药公司，从2017年3月至2018年6月。从2015年11月至2017年3月，他担任医疗技术公司Fractyl Laboratories，Inc.的财务总监。2014年6月至2015年11月，Green先生担任生物制药公司Dicerna Pharmaceuticals, Inc.的会计总监。从2013年11月到2014年6月，Green先生担任Corporate Finance Group，Inc.的高级经理，这是一家金融咨询公司。从2008年到2013年9月，Green先生担任普华永道会计师事务所（PricewaterhouseCoopers LLP，一家会计师事务所）的保证经理。Green先生是一名注册专业会计师，拥有阿卡迪亚大学化学和生物学学士学位。
- John Green has served as our Chief Financial Officer, principal accounting officer and principal financial officer since July 2020. Prior to his promotion, Mr. Green was our Vice President of Finance and Controller from April 2018 to June 2020.Prior to joining Cogent, Mr. Green served as Principal Accounting Officer at Merrimack Pharmaceuticals, Inc. Nasdaq: MACK, a biopharmaceutical company, from March 2017 to June 2018. From November 2015 to March 2017 he served as the Controller at Fractyl Laboratories, Inc., a medical technology company. From June 2014 to November 2015 Mr. Green served as Director of Accounting at Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a biopharmaceutical company. From November 2013 to June 2014 Mr. Green served as a Senior Manager at Corporate Finance Group, Inc., a financial consulting firm. From 2008 to September 2013 Mr. Green served as an Assurance Manager at PricewaterhouseCoopers LLP, an accounting firm. Mr. Green is a Chartered Professional Accountant and holds a B.S. in Chemistry and Biology from Acadia University.
- Jessica Sachs
Jessica Sachs自2019年6月起担任我们的首席医疗官。在担任该职位之前，她于2017年4月至2019年6月担任我们的临床科学副总裁，负责Cogent投资组合的临床开发战略以及医疗和转化监督。萨克斯博士在肿瘤学和儿科领域拥有超过16年的经验。从2012年到2017年4月，她曾担任Takeda Pharmaceutical Company Limited（全球生物制药公司）的临床研究高级医学总监，在那里她领导了肿瘤和移植的多个临床计划。从2010年到2012年，她曾担任健赞公司公司（生物技术公司）的副董事，在那里她负责多种肿瘤产品的上市后安全监督和风险管理活动。自2007年以来，萨克斯博士一直是哈佛医学院的一名教员，并在马萨诸塞州总医院的儿科血液学/肿瘤学部门担任儿科助理。她在Dana Farber癌症研究所和波士顿儿童医院完成了儿科血液学和肿瘤学研究。她在圣路易斯的华盛顿大学获得医学博士学位，在杜克大学获得学士学位。
Jessica Sachs has served as our Chief Medical Officer since June 2019. Prior to assuming this role, she served as our Vice President of Clinical Sciences from April 2017 to June 2019 and she was responsible for the clinical development strategy and medical and translational oversight of the Cogent portfolio. Dr. Sachs has over 16 years of experience in oncology and pediatrics. From 2012 to April 2017 Dr. Sachs served as Senior Medical Director of Clinical Research at Takeda Pharmaceutical Company Limited, a global biopharmaceutical company, where she led multiple clinical programs in oncology and transplantation. From 2010 to 2012 Dr. Sachs was Associate Director at Genzyme Corporation, a biotechnology company, where she was responsible for post-marketing safety surveillance and risk management activities for a variety of oncology products. Dr. Sachs has been a faculty member of the Harvard Medical School since 2007 and is an Assistant in Pediatrics in the Division of Pediatric Hematology/Oncology at the Massachusetts General Hospital. She completed her fellowship in pediatric hematology and oncology at the Dana Farber Cancer Institute and Children's Hospital Boston. She received her M.D. from Washington University in St. Louis and her B.S. from Duke University.- Jessica Sachs自2019年6月起担任我们的首席医疗官。在担任该职位之前，她于2017年4月至2019年6月担任我们的临床科学副总裁，负责Cogent投资组合的临床开发战略以及医疗和转化监督。萨克斯博士在肿瘤学和儿科领域拥有超过16年的经验。从2012年到2017年4月，她曾担任Takeda Pharmaceutical Company Limited（全球生物制药公司）的临床研究高级医学总监，在那里她领导了肿瘤和移植的多个临床计划。从2010年到2012年，她曾担任健赞公司公司（生物技术公司）的副董事，在那里她负责多种肿瘤产品的上市后安全监督和风险管理活动。自2007年以来，萨克斯博士一直是哈佛医学院的一名教员，并在马萨诸塞州总医院的儿科血液学/肿瘤学部门担任儿科助理。她在Dana Farber癌症研究所和波士顿儿童医院完成了儿科血液学和肿瘤学研究。她在圣路易斯的华盛顿大学获得医学博士学位，在杜克大学获得学士学位。
- Jessica Sachs has served as our Chief Medical Officer since June 2019. Prior to assuming this role, she served as our Vice President of Clinical Sciences from April 2017 to June 2019 and she was responsible for the clinical development strategy and medical and translational oversight of the Cogent portfolio. Dr. Sachs has over 16 years of experience in oncology and pediatrics. From 2012 to April 2017 Dr. Sachs served as Senior Medical Director of Clinical Research at Takeda Pharmaceutical Company Limited, a global biopharmaceutical company, where she led multiple clinical programs in oncology and transplantation. From 2010 to 2012 Dr. Sachs was Associate Director at Genzyme Corporation, a biotechnology company, where she was responsible for post-marketing safety surveillance and risk management activities for a variety of oncology products. Dr. Sachs has been a faculty member of the Harvard Medical School since 2007 and is an Assistant in Pediatrics in the Division of Pediatric Hematology/Oncology at the Massachusetts General Hospital. She completed her fellowship in pediatric hematology and oncology at the Dana Farber Cancer Institute and Children's Hospital Boston. She received her M.D. from Washington University in St. Louis and her B.S. from Duke University.